Clinical trials: Weight, Body
Overweight or Obesity
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing…
- Trial name
- NCT07685808
- Testing
- Olatorepatide
- Where
- 21 sites in United States
- Volunteers
- 360 people
- Sponsor
- Regeneron Pharmaceuticals
Overweight or Obesity Without Diabetes
Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
This study will test olatorepatide (study drug) to determine whether it can help treat overweight or obesity. In this study we will test how safe and how well olatorepatide works compared to placebo in people who are overweight…
- Trial name
- RISE-1 (NCT07896265)
- Testing
- Olatorepatide
- Volunteers
- 3,000 people
- Sponsor
- Regeneron Pharmaceuticals
Weight Loss
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type…
- Trial name
- NCT07868835
- Testing
- VK2735
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Weight Loss
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
- Trial name
- NCT07868939
- Testing
- VK2735 Oral
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the risk of serious health problems, including heart disease, type 2 diabetes, and other medical conditions.
- Trial name
- NCT07792954
- Testing
- Berobenatide
- Where
- 34 sites in China
- Volunteers
- 300 people
- Sponsor
- Pfizer
Obesity, Overweight
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity
Overweight and obesity are long-term health conditions that can increase the possibility of serious health problems. These problems include heart disease, type 2 diabetes (a condition that causes high blood sugar), and other…
- Trial name
- NCT07874633
- Testing
- Berobenatide
- Where
- 2 sites in China
- Volunteers
- 432 people
- Sponsor
- Pfizer
Obesity, Overweight and/or Obesity
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
- Trial name
- NCT07400653
- Testing
- PF-08653944
- Where
- 180 sites in United States, Argentina and 9 more
- Volunteers
- 1,078 people
- Sponsor
- Pfizer
Overweight, Obesity
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in…
- Conditions
- Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
- Trial name
- SOLIS-1 (NCT07575932)
- Testing
- PF-08653945, PF-08653944
- Where
- 63 sites in United States, Canada
- Volunteers
- 940 people
- Sponsor
- Pfizer
Obesity, Overweight and/or Obesity
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight
- Trial name
- NCT07595549
- Testing
- PF-08653944
- Where
- 72 sites in United States, Brazil and 9 more
- Volunteers
- 954 people
- Sponsor
- Pfizer
Obese But Otherwise Healthy Participants
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will…
- Trial name
- CANYON-1 (NCT07310901)
- Testing
- CRB-913
- Where
- 15 sites in United States
- Volunteers
- 254 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Diabetes Mellitus, Type 2
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with…
- Trial name
- MARITIME-T2D-3 (NCT07866066)
- Testing
- Maridebart cafraglutide, Semaglutide
- Volunteers
- 1,300 people
- Sponsor
- Amgen
Obese, Overweight Adults
A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults
The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults.
- Conditions
- Obese, Overweight Adults, Obese Adults, Body Weight Control
- Trial name
- NCT07363148
- Testing
- MB-1
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Arrae
Facial Subcutaneous Fullness, Subcutaneous Fat Accumulation
Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of high-dose oral 70 kDa hyaluronan (HA35) for aesthetic improvement.
- Conditions
- Facial Subcutaneous Fullness, Subcutaneous Fat Accumulation, Facial Inflammatory Erythema, Dull Skin
- Trial name
- HA35-ORAL (NCT07583108)
- Testing
- High-Dose Oral 35 kDa Hyaluronan (HA35)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nakhia Impex LLC
Healthy
A Study of LY3549492 in Healthy Weight Adult Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2).
- Trial name
- NCT07085468
- Testing
- LY3549492
- Where
- 21 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Obesity
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
- Trial name
- MARITIME-1 (NCT06858839)
- Testing
- Maridebart Cafraglutide
- Where
- 243 sites in United States, Argentina and 15 more
- Volunteers
- 3,853 people
- Sponsor
- Amgen
Body Weight Management
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity
This study is a single-center, randomized, double-blind, dose-escalation, placebo-parallel-controlled Phase I clinical trial. The primary objective is to evaluate the safety and tolerability of a single subcutaneous injection of…
- Trial name
- NCT07826364
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Health, Wellness
An Open Label Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes
The purpose of this study is to: 1. Understand the participant experience using a health and wellness product and effects of the study product on GLP-1 users and those trying to lose weight 2.
- Conditions
- Health, Wellness, Quality of Life
- Trial name
- NCT07563855
- Testing
- A ready-to-mix beverage containing protein, fiber, and electrolytes
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Diabetes Type 2, Diabetes
Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes
This is a prospective, multicenter, randomized, double-blind, sham-controlled, adaptive study evaluating the pulsENDO system in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering…
- Conditions
- Diabetes Type 2, Diabetes, Diabetes (DM), Weight Change
- Trial name
- pulsENDO (NCT07768631)
- Testing
- pulsENDO Therapy
- Volunteers
- 320 people
- Sponsor
- Endogenex, Inc.
Metabolic Health, Weight Management
A Clinical Trial to Evaluate the Effects of A Supplement on Supporting Signs of Metabolic Health
This study evaluates the effects of the Love Wellness supplement Hello Burn Activate on supporting metabolic health in adult females.
- Conditions
- Metabolic Health, Weight Management, Body Confidence, Gut Health
- Trial name
- NCT07765394
- Testing
- Hello Burn Activate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Love Wellness
Chronic Management of Body Weight
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
- Trial name
- NCT07670884
- Testing
- HRS9531 Tablet
- Where
- 2 sites in China
- Volunteers
- 675 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.